Stingray Bio, a biotechnology company headquartered in Sussex UK, is focused on the discovery and development of novel small molecule cancer therapeutics targeting the LMTK3 kinase signaling pathway. The LMTK3 kinase pathway has been extensively validated as an essential component of cancer survival and growth in breast and other common cancer types. The Company is developing novel drug inhibitors of LMTK3 kinase signalling towards diverse clinical applications. By targeting neglected but essential cancer kinases, the Company aims to generate next-generation oncology therapeutics for cancer patients.

Status Active
Website http://www.stingraybio.com/
Category Biotech
Modality Small Molecule
Therapautics Area
Headquaters Cambridge, UK
Investment Portfolio Fund Investment